Genmab — December 2018

[E_L]

Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
https://www.prnewswire.com/news-releases/regeneron-presents-positive-data-at-ash-for-regn1979-cd20xcd3-bispecific-antibody-in-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma-300758615.html

[Solsen]

Wau that is spectacular. Insteresting to se the first CD3 results from Genmabs pipeline.

[Solsen]

Could indicate that this route could be better than the CAR-T.

[Sukkeralf]

Also what Jan said that Regenerons bispecific was as good as CAR-T. Inpressive efficacy

[Solsen]

If Genmab want anything with their CD20 x CD3 they need a partner now. Otherwise they could be too late out.

[E_L]

oh, did he, i missed that, interesting.

[E_L]

mmm, yes, that is an interesting thought, they need to be fast now…..

[Solsen]

I belive Roche could be eager to license.

[Solsen]

Yes JW have said as Sukkeralf reffering.

[Sukkeralf]

Jan also mentioned that Roche/Genentech had 3 CD3/CD20 BsAb - two in the clinic and one preclinical. So guess not interested begore Genmab present outstanding data

[Solsen]

I dont think the bite technology is competitive

[Sukkeralf]

Too old - was it regeneron that also had a BCMA-CD3 BsAb at ASH ?

[E_L]

i guess it is too early to expect any data from Genmab´s cd3cd20 presentation tonight?

[Sukkeralf]

Way too early - maybe ASH next year

[Solsen]

If you work with three bsabs at Genentech it certainly dont look like they have found the needle in the haystack

[bibob]

Maybe Genmab have the needle.

[Sukkeralf]

Jan said Its because Its so hard to predict what you exactly need - three is better than one

[Sukkeralf]

But nice data for BsAbs will give more value to Genmabs preclinical and early pipeline as it based on this

[Solsen]

Discontinuation was relative high in Regenerons trial. The silencing of the CD3 arm could be the right way

[Bulder]

Just a detail: It's not the cd3-arm that is silenced. It's the Fc-part.